2017
Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge”, Napoli, November 30th 2016
Ascierto PA, Daniele B, Hammers H, Hirsh V, Kim J, Licitra L, Nanda R, Pignata S. Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge”, Napoli, November 30th 2016. Journal Of Translational Medicine 2017, 15: 205. PMID: 29020960, PMCID: PMC5637331, DOI: 10.1186/s12967-017-1309-2.Peer-Reviewed Original ResearchConceptsTypes of cancerAnti-PD-1/PD-L1 monotherapyPlatinum-refractory metastatic urothelial carcinomaResponse rateImmune systemPD-L1/PDFirst-line monotherapyImmunotherapy-responsive diseasePD-L1 monotherapyPre-treated NSCLCAddition of chemotherapyDiscontinuation of therapyMetastatic urothelial carcinomaMetastatic breast cancerUse of nivolumabMetastatic renal carcinomaImmune checkpoint receptorsModest response ratesHigh response rateLess side effectsMultiple oncogenic pathwaysImmunotherapy BridgeLine monotherapyAdvanced NSCLCMetastatic NSCLC
2015
Emerging immunotherapies for bladder cancer
Kim JW, Tomita Y, Trepel J, Apolo AB. Emerging immunotherapies for bladder cancer. Current Opinion In Oncology 2015, 27: 191-200. PMID: 25811346, PMCID: PMC7709951, DOI: 10.1097/cco.0000000000000177.Peer-Reviewed Original ResearchConceptsUrothelial carcinomaImmune escapeImmune systemTumor antigen presentationAdvanced urothelial carcinomaBenefit of immunotherapyImmune escape mechanismsFraction of patientsHigh mutational burdenImmune-mediated cytotoxicityMultiple tumor typesDurable responsesImmune checkpointsBladder cancerClinical trialsT cellsCombinatorial regimensTumor antigensMutational burdenImmunotherapyClinical developmentCarcinomaTumor typesTumor cellsEscape mechanisms